

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad, 500 034, AP, India

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2014

PART - I

Amount in ₹ Lacs

SI.	Particulars	Quarter	Ouartor		Tount in 7 Lacs
No.	Turicatura	Ended	Quarter Ended	Quarter	Year
	'	30.06.2014	31.03.2014	Ended	Ended
	,	(Unaudited)	(Unaudited)	30.06.2013	31.03.2014
		(Onaudited)	(Ullaudited)	(Unaudited)	(Audited)
1	Income from Operations	1			
	(a) Net Sales / Income from Operations	10,267.45	10,926.25	12,131.84	46,569.33
	(b) Other Operating Income	73.44	116.09	72.08	341.48
	Total Income from Operations (Net)	10,340.89	11,042.34	12,203.92	46,910.81
2	Expenses	'		1	
	(a) Consumption of Raw Materials	6,368.23	5,986.13	6,352.93	24,644.22
'	(b) Changes in inventories of finished goods				
'	and work in process	(922.35)	(348.64)	465.63	12.80
'	(c) Employee Benefit Expense	1,054.44	942.66	963.52	3,625.51
'	(d) Depreciation	389.90	390.14	365.18	1,493.86
'	(e) Manufacturing Expenses	1,241.51	1,312.83	993.61	4,842.24
'	(f) Other Expenses	1,165.17	1,330.30	1,368.30	6,506.06
'	Total Expenses	9,296.90	9,613.42	10,509.17	41,124.69
	Profit from Operations before Finance Costs (1-2)	1,043.99	1,428.92	1,694.75	5,786.12
4	Finance Costs	567.82	547.82	590.05	2,363.76
	Profit / (Loss) before Tax (3-4)	476.17	881.10	1,104.70	3,422.36
6	Tax Expense	1			,
1	(a) Current tax	103.90	190.60	210.50	716.70
1 !	(b) Deferred Tax	173.83	22.28	323.60	755.61
	(c) MAT Credit entitlement	(103.90)	(190.60)	(210.50)	(716.70)
7	Net Profit / (Loss) for the period (5-6)	302.34	858.82	781.10	2,666.75
1 1	Paid-up Equity Share Capital				
	(Face Value ₹10 per share)	772.63	772.63	771.56	772.63
9	Reserves excluding Revaluation Reserve as per balance	1 *	1	1	1
1	sheet of previous accounting year	/	1		11,392.57
10	Earnings per Share (EPS) (in ₹)				
1	(a) Basic	3.95	11.22	10.22	34.87
1 1	(b) Diluted	3.95	11.22	10.21	34.86
	(4-2		5

CIN: L85195TG1984PLC004393



PAR	PART - II						
SI.	Particulars	Quarter	Quarter	Quarter	Year		
No.		Ended	Ended	Ended	Ended		
		30.06.2014	31.03.2014	30.06.2013	31.03.2014		
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
Α	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding						
	(a) Number of Shares	38,22,899	38,22,899	38,17,199	38,22,899		
	(b) Percentage of Shareholding	49.94%	49.94%	49.93%	49.94%		
2	Promoters and Promoter Group Shareholding	,					
	(a) Pledged / Encumbered						
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000		
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%		
	-Percentage of Shares (as a % of the total share capital of the Company)	2.61%	2.61%	2.62%	2.61%		
	(b) Non-encumbered						
	-Number of Shares	36,32,779	36,32,779	36,27,779	36,32,779		
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%		
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	47.45%	47.45%		

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.06.2014
Pending at the beginning of the quarter	0
Received during the quarter	9
Disposed off during the quarter	9
Remaining unresolved at the end of the quarter	0

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on July 31, 2014, and approved and taken on record at the Board of Directors meeting held on August 1, 2014.
- 2 EPS for the quarters is not annualised.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard AS 17 "Segment Reporting".
- 4 The Board had on July 17, 2014, issued and allotted 2,300 fully paid up equity shares of a face value of ₹10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008.
- 5 In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and:
 - i) An amount of ₹98.84 lakhs has been adjusted to the opening balance of Reserves & Surplus in respect of those assets where the useful life exhausted as at April 1, 2014
 - ii) The profit for the quarter has decreased by ₹11.99 lakhs on account higher depreciation due to application of Schedule II.
- 6 Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board For Neuland Laboratories Limited

Dr. D.R.Rao

Chairman & Managing Director

Place: Hyderabad Date: August 1, 2014

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP (Formerly Walker, Chandiok & Co) 7th Floor, Block III, White House Kundan Bagh, Begumpet Hyderabad 500016 India

T +91 40 6630 8200 F +91 40 6630 8230

Review Report

To the Board of Directors of Neuland Laboratories Limited

- 1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Neuland Laboratories Limited ("the Company") for the quarter ended 30 June 2014, except for the disclosures regarding Public Shareholding' and Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Walker Chandiok & Co LLP

4. The review of financial results for the three months period ended 30 June 2013 included in the Statement was carried out and reported by K.S. Aiyar & Co, Chartered Accountants, vide their unqualified review report dated 2 August 2013 whose review report has been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our review report is not qualified in respect of this matter.

andiox

Lour Chardion Ses Up For Walker Chandiok & Co LLP

(formerly Walker, Chandiok & Co)

Chartered Accountants

Firm Registration No: 001076N/N500013

per Sanjay Kumar Jain

Partner

Membership No. 207660

Place: Hyderabad Date: 01 August 2014